Novel chimeric antigen receptor and application thereof
A chimeric antigen receptor, antigen technology, applied in the field of biomedical transformation
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0072] Example 1, Design of Recombinant Chimeric Antigen Receptors with Light-Inducible Elements
[0073] The present invention selects the CD19-CAR gene with better clinical effect, and the constituent elements are as follows: CD19 scFv, CD8hinge, CD8 transmembrane, 4-1BB intracellular, CD3ζ;
[0074] LOV2 used in the present invention (aa 404-546 of Avena sativa Phototropin 1, NPH1-1, GenBank: AAC05083.1) derived from oat ( Avena sativa ), according to people ( Homo spaice ) codon preference for codon optimization, the amino acid sequence is shown in SEQ ID No: 1, and the nucleotide sequence is shown in SEQ ID No: 13.
[0075] Insert LOV2 into the CD19-CAR antigen binding region, transmembrane structure region, co-stimulatory signal transduction region and T cell signal transduction region before and after or between the functional domains, as follows:
[0076] liCAR5: CD19 scFv-connecting peptide 1-LOV2-connecting peptide 2-CD8 hinge region-CD8 transmembrane domain-4...
Embodiment 2
[0082] Example 2, Expression of Recombinant Chimeric Antigen Receptors with Light-Inducible Elements
[0083] 1. Construction of co-expression vectors Lenti-liCAR5, Lenti-liCAR6, Lenti-liCAR7, Lenti-liCAR8 and Lenti-liCAR9
[0084] Lenti-EF1α-CD19CAR (CD3ZetaQQ) was purchased from iCartab Biomedical Technology (Suzhou) Co., Ltd. (http: / / www.icartab.com.cn). Plasmid pUCK-AsLOV2 was purchased from the company.
[0085] Using the classic CD19-CAR molecule (SEQ ID No: 45) and the LOV2 molecule (SEQ ID No: 13) optimized according to human codon preference as templates, the primers were designed as follows:
[0086] liCAR5:
[0087] CALOV (EcoRI): 5'-TTCGAATTCGCCGCCACCATG-3' SEQ ID No: 29;
[0088] CALOV5aR: 5'-GCTCCCACTCCCGCTTCCGCTGGACACGGTGACCAGA-3' SEQ ID No: 33;
[0089] GSLOVF: 5'-GGAAGCGGGAGTGGGAGCCTTGCAACCACCTTGGAAAG-3' SEQ ID No: 31;
[0090] EALOVR: 5'-CCGCTGCTTCTTTGGCCGCTGCTTCCAGCTCTTTGGCGGCCTCATC-3' SEQ ID No: 32;
[0091] EALOV5cF: 5'-AGCGGCCAAAGAAGCAGCGGCCAAAACCACTA...
Embodiment 3
[0131] Example 3. Study on the Killing Activity of Recombinant Chimeric Antigen Receptor T Cells with Light-Inducible Elements
[0132] Inoculate 100 μl 1×10 4 Target cells (leukemia cells Raji) per well were added to 96-well cell culture plates, and Jurkat-CAR5, Jurkat-CAR6, Jurkat-CAR7, Jurkat-CAR8, Jurkat-CAR9 cells (expressing liCAR5 -9 Jurkat cells), make up the culture solution to 200μl, respectively, under light conditions (LED light, 465nm, 30μmolm -2 the s -1 , exposure for 4h) and 37°C, 5% CO under dark conditions 2 The incubator co-cultured for 48h.
[0133] (1) Experiment 1
[0134] After 48 hours of co-cultivation, the cell culture suspensions were collected and centrifuged to collect the supernatant, and the IL-2 content was detected using the human IL-2 ELISA kit. For specific steps, refer to the instruction manual of the human IL-2 ELISA kit. Specific results such as figure 2 shown. figure 2 It shows that the IL-2 activity of Jurkat-CAR5, Jurkat-CAR6,...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com